BCR
C. R. Bard, Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 12:12 PM
    • Investors' sour mood with Medtronic (MDT -10.2%) over its modest 2% fiscal Q2 revenue miss has spread to Abbott (ABT -4.6%), Edwards Lifesciences (EW -5.6%) and Boston Scientific (BSX -4.4%).
    • Others feeling the pinch are Stryker (SYK -2.3%) and C.R. Bard (BCR -3.6%).
    | Tue, Nov. 22, 12:12 PM | 18 Comments
  • Tue, Oct. 25, 5:12 PM
    • C.R. Bard (NYSE:BCR) Q3 results ($M): Total Revenues: 941.9 (+8.8%); Vascular: 258.1 (+3.0%); Urology: 242.1 (+14.0%); Oncology: 258.4 (+8.0%); Surgical Specialties: 158.8 (+13.6%).
    • Net Income: 96.4 (+212.1%); Non-GAAP Net Income: 199.5 (+14.2%); EPS: 1.27 (+209.5%); Non-GAAP EPS: 2.64 (+15.8%).
    • 2016 Guidance: Revenue Growth: 8 - 9%; Non-GAAP EPS: $10.23 - 10.28.
    • Q3 revenues were 1.1% above consensus of $931.7M and non-GAAP EPS was 3.5% above consensus of $2.55.
    • Q4 consensus is non-GAAP EPS of $2.74 on revenues of $943.4M.
    | Tue, Oct. 25, 5:12 PM | 1 Comment
  • Tue, Oct. 25, 4:22 PM
    • C. R. Bard (NYSE:BCR): Q3 EPS of $2.64 beats by $0.09.
    • Revenue of $941.9M (+8.8% Y/Y) beats by $10.24M.
    • Press Release
    | Tue, Oct. 25, 4:22 PM
  • Mon, Oct. 24, 5:35 PM
    | Mon, Oct. 24, 5:35 PM | 20 Comments
  • Wed, Oct. 12, 4:29 PM
    • C. R. Bard (NYSE:BCR) declares $0.26/share quarterly dividend, in line with previous.
    • Forward yield 0.48%
    • Payable Nov. 4; for shareholders of record Oct. 24; ex-div Oct. 20.
    | Wed, Oct. 12, 4:29 PM
  • Fri, Sep. 16, 12:07 PM
    • C.R. Bard (NYSE:BCR) upgraded to Outperform from Market Perform by Wells Fargo.
    • DexCom (NASDAQ:DXCM) upgraded to Buy from Hold by Desjardins. Downgraded to Neutral from Buy with a $92 (1% downside risk) price target by BTIG Research.
    • Alimera Sciences (NASDAQ:ALIM) upgraded to Outperform from Market Perform by Cowen & Company.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $47 (13% downside risk) from $30.
    • Akorn (NASDAQ:AKRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $34 (19% upside) from $33.
    • Community Health Systems (NYSE:CYH) upgraded to Positive from Neutral by Susquehanna. Price target raised to $18 (66% upside).
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold by Jefferies. Price target raised to GBX 5,800 (14% upside) from GBX 5,400. Downgraded to Neutral from Outperform with a GBX 5,200 (2% upside) price target by BNP Paribas.
    • McKesson (NYSE:MCK) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $189 (15% upside) from $210.
    • Cardinal Health (NYSE:CAH) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $83 (8% upside) from $90.
    • Novavax (NASDAQ:NVAX) downgraded to Neutral from Outperform by Wedbush. Price target lowered to $2 (44% upside) from $14. Downgraded to Neutral from Buy by Citigroup. Price target lowered to $1.50 (8% upside) from $12. Downgraded to Neutral from Overweight by JPMorgan and Piper Jaffray.
    • Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Market Perform from Outperform by Cowen & Company.
    • Vitae Pharmaceuticals (NASDAQ:VTAE) downgraded to Market Perform from Outperform by BMO Capital.
    • Atara Biotherapeutics (NASDAQ:ATRA) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $16 (18% downside risk) from $23.
    • GlaxoSmithKline (NYSE:GSK) downgraded to Underperform from Neutral with a GBX 1,520 (6% downside risk) price target by BNP Paribas.
    • Applied Genetic Technologies (NASDAQ:AGTC) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $12 (34% upside) from $34. Downgraded to Hold from Buy by Cantor Fitzgerald. Price target lowered to $15 (68% upside) from $32.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Outperform by Baird.
    | Fri, Sep. 16, 12:07 PM | 8 Comments
  • Fri, Sep. 16, 7:13 AM
    • Baxter International (NYSE:BAX) initiated with Overweight rating and $52 (11% upside) price target by Barclays.
    • Sophiris Bio (NASDAQ:SPHS) initiated with Buy rating and $8 (170% upside) price target by Roth Capital.
    • C.R. Bard (NYSE:BCR) initiated with Buy rating and $235 (5% upside) price target by Evercore ISI.
    • Health Insurance Innovations (NASDAQ:HIIQ) initiated with Buy rating and $9 (82% upside) price target by Lake Street Capital.
    • ViewRay (NASDAQ:VRAY) initiated with Buy rating and $6 (60% upside) price target by BTIG Research.
    • Aerie Pharmaceuticals (NASDAQ:AERI) initiated with Strong Buy rating and $48 (57% upside) price target by Raymond James.
    • Vertex Pharmaceuticals (NASDAQ:VRTX) initiated with Market Perform rating by Raymond James.
    • Mirna Therapeutics (NASDAQ:MIRN) initiated with Buy rating and $6 (155% upside) price target by H.C. Wainwright.
    • Oasmia Pharmaceutical AB (NASDAQ:OASM) initiated with Buy rating and $6 (82% upside) price target by Rodman & Renshaw.
    • Gilead Sciences (NASDAQ:GILD) initiated with Buy rating and $112 (42% upside) price target by Berenberg Bank.
    | Fri, Sep. 16, 7:13 AM | 11 Comments
  • Tue, Aug. 2, 7:06 AM
    • July monthly performance was: +2.28%
    • AUM of $2.39B
    • 52-week performance vs. the S&P 500 is: +7%
    • No dividends were paid in July
    • Top 10 Holdings as of 6/30/2016: McCormick & Co Inc Non-Voting (MKC): 2.25805%, Cincinnati Financial Corp (CINF): 2.25221%, AT&T Inc (T): 2.2047%, C.R. Bard Inc (BCR): 2.20417%, Clorox Co (CLX): 2.19531%, Consolidated Edison Inc (ED): 2.18289%, Sysco Corp (SYY): 2.15335%, Medtronic PLC (MDT): 2.13378%, Cintas Corp (CTAS): 2.12501%, Kimberly-Clark Corp (KMB): 2.10475%
    | Tue, Aug. 2, 7:06 AM
  • Tue, Jul. 26, 4:21 PM
    • C. R. Bard (NYSE:BCR): Q2 EPS of $2.54 beats by $0.07.
    • Revenue of $931.5M (+8.3% Y/Y) beats by $16.28M.
    • Press Release
    | Tue, Jul. 26, 4:21 PM | 1 Comment
  • Mon, Jul. 25, 5:35 PM
  • Fri, Jul. 1, 7:03 AM
    • June monthly performance was: +2.86%
    • AUM of $2.02B
    • 52-week performance vs. the S&P 500 is: +7%
    • $0.25 in dividends were paid in June
    • Top 10 Holdings as of 5/31/2016: S&P Global Inc (SPGI): 2.15464%, Archer-Daniels Midland Co (ADM): 2.15039%, Cincinnati Financial Corp (CINF): 2.13109%, McCormick & Co Inc Non-Voting (MKC): 2.10728%, C.R. Bard Inc (BCR): 2.10554%, Cintas Corp (CTAS): 2.10524%, Leggett & Platt Inc (LEG): 2.10068%, Lowe's Companies Inc (LOW): 2.09886%, Brown-Forman Corp Class B (BF.B): 2.09499%, Pentair PLC (PNR): 2.09495%
    | Fri, Jul. 1, 7:03 AM
  • Mon, Jun. 27, 11:16 AM
    | Mon, Jun. 27, 11:16 AM | 83 Comments
  • Wed, Jun. 8, 5:16 PM
    • C. R. Bard (NYSE:BCR) declares $0.26/share quarterly dividend, 8.3% increase from prior dividend of $0.24.
    • Forward yield 0.46%
    • Payable July 29; for shareholders of record July 18; ex-div July 14.
    | Wed, Jun. 8, 5:16 PM | 1 Comment
  • Wed, Jun. 8, 4:41 PM
    • The board of C.R. Bard (NYSE:BCR) authorizes the repurchase of up to $500M of the company's common stock, an additional amount to the current ~$205M remaining under the prior authorization announced almost a year ago.
    | Wed, Jun. 8, 4:41 PM | 1 Comment
  • Thu, Jun. 2, 7:46 AM
    • May monthly performance was: +0.76%
    • AUM of $1.77B
    • 52-week performance vs. the S&P 500 is: +7%
    • No dividends were paid in May
    • Top 10 Holdings as of 4/30/2016: Consolidated Edison Inc (ED): 2.09%, Leggett & Platt Inc (LEG): 2.07%, S&P Global Inc (SPGI): 2.07%, Brown-Forman Corp Class B (BF.B): 2.07%, Colgate-Palmolive Co (CL): 2.06%, C.R. Bard Inc (BCR): 2.05%, Hormel Foods Corp (HRL): 2.05%, W.W. Grainger Inc (GWW): 2.05%, Clorox Co (CLX): 2.05%, McCormick & Co Inc Non-Voting (MKC): 2.05%
    | Thu, Jun. 2, 7:46 AM
  • Wed, Apr. 27, 4:38 PM
    • C.R. Bard (NYSE:BCR) Q1 results ($M): Total Revenues: 873.5 (+6.6%); Vascular: 239.5 (+3.3%); Urology: 216.7 (+5.4%); Oncology: 241.9 (+7.7%); Surgical Specialties: 151.4 (+11.4%).
    • Net Income: 116.2 (-16.9%); Non-GAAP Net Income: 177.0 (+9.5%); EPS: 1.54 (-15.4%); Non-GAAP EPS: 2.34 (+11.4%).
    • 2016 Guidance: Revenue growth: 6 - 8%; Non-GAAP EPS: $10.05 - 10.18.
    | Wed, Apr. 27, 4:38 PM